Ionis partner Roche's sefaxersen cuts proteinuria 43.1% versus placebo in Phase 3 IgAN trial

By Public Technologies
  • Ionis partner Roche reported sefaxersen reduced proteinuria 43.1% versus placebo at 37 weeks in the Phase 3 IMAgINATION trial for IgA nephropathy.
  • The reduction was statistically significant (95% confidence interval: 32.5%-52%; P<0.0001), with consistent treatment effects across all prespecified subgroups.
  • Sefaxersen, an investigational monthly injection designed for self-administration, was well tolerated, with no new safety signals.
  • The blinded trial will continue to assess kidney function at week 105; Roche plans to share results with health authorities.
  • The licensing agreement provides eligibility for regulatory and sales milestone payments, plus tiered royalties on sefaxersen net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-040631), on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.